Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma

被引：34

作者：

Axelrod, M. ^{[1
]}

Ou, Z. ^{[2
]}

Brett, L. K. ^{[3
]}

Zhang, L. ^{[2
]}

Lopez, E. R. ^{[2
]}

Tamayo, A. T. ^{[2
]}

Gordon, V. ^{[1
]}

Ford, R. J. ^{[4
]}

Williams, M. E. ^{[3
]}

Pham, L. V. ^{[4
]}

Weber, M. J. ^{[1
]}

Wang, M. L. ^{[2
]}

机构：

[1] Univ Virginia Hlth Syst, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[3] Univ Virginia Hlth Syst, Div Hematol Oncol, Charlottesville, VA USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

LEUKEMIA | 2014年 / 28卷 / 02期

关键词：

BTK; IMMUNOCHEMOTHERAPY; IBRUTINIB; RESISTANT;

D O I：

10.1038/leu.2013.249

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：407 / 410

页数：5

共 17 条

[1] The toxicity of poisons applied jointly [J].

Bliss, CI .

ANNALS OF APPLIED BIOLOGY, 1939, 26 (03) :585-615

[2] A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) [J].

Blum, Kristie A. ;

Christian, Beth ;

Flynn, Joseph M. ;

Jaglowski, Samantha M. ;

Jones, Jeffrey Alan ;

Maddocks, Kami ;

Byrd, John C. .

BLOOD, 2012, 120 (21)

[3] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[4]

Chang BY, 2013, J CLIN ONCOL, V31

[5] The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib [J].

Dasmahapatra, Girija ;

Patel, Hiral ;

Dent, Paul ;

Fisher, Richard I. ;

Friedberg, Jonathan ;

Grant, Steven .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) :43-56

[6] Circumventing Cancer Drug Resistance in the Era of Personalized Medicine [J].

Garraway, Levi A. ;

Jaenne, Pasi A. .

CANCER DISCOVERY, 2012, 2 (03) :214-226

[7] Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer [J].

Gioeli, Daniel ;

Wunderlich, Winfried ;

Sebolt-Leopold, Judith ;

Bekiranov, Stefan ;

Wulfkuhle, Julia D. ;

Petricoin, Emanuel F., III ;

Conaway, Mark ;

Weber, Michael J. .

MOLECULAR CANCER THERAPEUTICS, 2011, 10 (09) :1581-1590

[8] KEGG: Kyoto Encyclopedia of Genes and Genomes [J].

Kanehisa, M ;

Goto, S .

NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :27-30

[9] Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 [J].

Liu, Hongtao ;

Johnson, Jeffrey L. ;

Koval, Greg ;

Malnassy, Greg ;

Sher, Dorie ;

Damon, Lloyd E. ;

Hsi, Eric D. ;

Bucci, Donna Marie ;

Linker, Charles A. ;

Cheson, Bruce D. ;

Stock, Wendy .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04) :579-585

[10] Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome [J].

Parlati, Francesco ;

Lee, Susan J. ;

Aujay, Monette ;

Suzuki, Erika ;

Levitsky, Konstantin ;

Lorens, James B. ;

Micklem, David R. ;

Ruurs, Paulina ;

Sylvain, Catherine ;

Lu, Yan ;

Shenk, Kevin D. ;

Bennett, Mark K. .

BLOOD, 2009, 114 (16) :3439-3447

← 1 2 →